title: Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.
abstract: BACKGROUND
  There is increasing pressure for the recognition and replication of good clinical practice. We undertook a study to assess the variability in outcome of allogeneic bone-marrow transplantation among major European centres.
  
  
  METHODS
  We studied 13 centres, including 522 patients (aged 16-55 years), which had undertaken more than 30 bone-marrow transplantations between Jan 1, 1987, and Dec 31, 1995, for acute myeloid leukaemia in first complete remission. We undertook a (global) multivariate analysis of all factors known previously to influence outcome and a stratified analysis that initially defined, by multivariate analysis, significant variables in this study and then used a proportional-hazard model including centres.
  
  
  RESULTS
  The overall results at 3 years were 57% (95% CI 53-61) for leukaemia-free survival (LFS), 23% (19-27) for relapse incidence (RI), and 26% (22-30) for treatment-related mortality (TRM) with a range for centres of 36-75%, 10-37%, and 8-54%, respectively. Both methods of analysis showed the centre effect to be highly significant for LFS and TRM, but not for RI. Variables associated with a significantly poor outcome were age over 43 years (p=0.01), time from diagnosis to first complete remission longer than 65 days (p=0.02), and centre (p=0.013) for LFS, and age over 43 years (p=0.023), time from first complete remission to transplantation of longer than 93 days (p=0.03), and centre (p=0.001) for TRM. Moreover, different centres had different prognostic criteria for good-risk or bad-risk patients indicating that risk factors do not have the same impact in each individual centre.
  
  
  CONCLUSIONS
  The outcome of bone-marrow transplantation for acute myeloid leukaemia in first complete remission is influenced by the centre in which the procedure is done, even with adjustment for known prognostic risk factors. Significant prognostic factors vary among centres, which means that the relative risk is not the same in each individual centre. However, centres may treat populations with different risks of as yet unidentified prognostic factors. Experience may partly account for the difference in outcome among centres.
authors.affiliation: Divisione Ematologia II, Ospedale San Martino, Genova, Italy. frafrassoni@smartino.ge.it
authors.forename: F
authors.initials: F
authors.lastname: Frassoni
authors.forename: M
authors.initials: M
authors.lastname: Labopin
authors.forename: R
authors.initials: R
authors.lastname: Powles
authors.forename: J Y
authors.initials: JY
authors.lastname: Mary
authors.forename: W
authors.initials: W
authors.lastname: Arcese
authors.forename: A
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: D
authors.initials: D
authors.lastname: Bunjes
authors.forename: E
authors.initials: E
authors.lastname: Gluckman
authors.forename: T
authors.initials: T
authors.lastname: Ruutu
authors.forename: U W
authors.initials: UW
authors.lastname: Schaefer
authors.forename: J
authors.initials: J
authors.lastname: Sierra
authors.forename: J P
authors.initials: JP
authors.lastname: Vernant
authors.forename: R
authors.initials: R
authors.lastname: Willemze
authors.forename: T
authors.initials: T
authors.lastname: de Witte
authors.forename: N C
authors.initials: NC
authors.lastname: Gorin
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality*; D018572:Disease-Free Survival; D005060:Europe; D005260:Female; D006801:Humans; D015994:Incidence; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D012307:Risk Factors